His nomination to head the HHS by President-elect Donald Trump on Thursday could bring sweeping changes to the way Washington, D.C., targets health issues.

Scientists at deCODE genetics and collaborators have published a study in the Journal of Allergy and Clinical Immunology ...

"Tivic hits enrolment target for vagus nerve stimulation trial" was originally created and published by Medical Device ...

Scientists at deCODE genetics, a subsidiary of Amgen, and collaborators have published a study in Journal of Allergy and ...

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

Researchers at Ayass Bioscience have discovered and developed AYA22A aptamers, molecular compounds that target and bind to ...

SPR206 is an investigational, intravenously administered next-generation polymyxin that has shown antibiotic activity against MDR Gram-negative pathogens, including carbapenem-resistant ...

AMPAR is a clinically promising human drug target in sporadic ALS (S-ALS). SPM-0404 is in IND-enabling studies as a potential oral treatment for three indications (1) CBT, (2) epilepsy, and (3) S-ALS.

The abrupt transition from sleep to a full-blown migraine leaves little room for preemptive action, especially when traditional oral migraine medications can take half an hour to an hour ... Ask your ...

Drugs to treat gastrointestinal and cardiovascular diseases, painkillers and anti-diabetic medicines recorded the maximum ...

Medically reviewed by Allison Herries, RDN Saffron, a widely used spice and colorant derived from the Crocus sativus (C.

Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive ...